Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

130 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06740370 2025-08-14

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Phase NA Recruiting

32 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05101629 2025-07-23

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Phase 2 Completed

32 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Phase NA Not yet recruiting

234 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT07052448 2025-07-04

The Efficacy of Sequential RT After Triple Therapy for uHCC

Enrolling by invitation

35 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07047586 2025-07-03

LEAF-01

Phase 2 Recruiting

146 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

53 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT07014150 2025-06-10

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05024214 2025-05-29

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

170 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06984718 2025-05-22

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Phase 2 Not yet recruiting

120 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Phase 2 Recruiting

160 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT06904196 2025-04-29

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Phase 2 Recruiting

78 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

CheckMate 9DW

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

BLP-HCC

LEAP-002

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

FRONT-1

TREMENDOUS-2

SLIDE-HCC

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

LEAP-012

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

ALIVE

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

KEYVIBE-005

LIVIGNO-1

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

The Efficacy of Sequential RT After Triple Therapy for uHCC

LEAF-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

CCGLC-001

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC